By Jeannette Wick
Researchers believe the less-invasive nature of transcatheter aortic-valve replacement systems allows patients to mobilize and recover in as little as one week, which contributes to the device's greater survival benefit compared to open-heart surgery.
By W. Todd Penberthy, PhD
The ACC/AHA cholesterol guideline can be a powerful tool for making multifactorial measures of cardiovascular disease risk assessment, particularly in African American populations, but clinicians should be aware of its limitations.
Graves disease is more common in blacks and Asian/Pacific Islanders compared with whites, according to a research letter published in the April 16 issue of the Journal of the American Medical Association.
Many Americans are paying less for prescription drugs, but some are having to deal with sharp rises in the cost of specialty medicines for rare or serious diseases, according to a new report.
Children born to mothers who gain either too much or too little weight during their pregnancy are more likely to be overweight or obese, according to a study published online April 14 in the American Journal of Obstetrics & Gynecology.
By Rachel Lutz
The European Medicines Agency has announced it will evaluate all medications containing testosterone for cardiovascular risk.
Short-term intensive insulin therapy can improve β-cell function in type 2 diabetes mellitus in association with decreased glycemic variability, according to a study published in the April issue of Diabetes Care.
In areas with less access to ophthalmologists, fewer individuals with diabetes, diabetic retinopathy, and age-related macular degeneration receive care, according to a study published in the April issue of JAMA Ophthalmology.
By HCP Live Staff
The US Food and Drug Administration has approved Tanzeum (albiglutide), a once-weekly subcutaneous injection for the treatment of type 2 diabetes in adults.
With the resignation of US Health and Human Services Secretary Kathleen Sebelius on Friday, the Affordable Care Act will get a fresh face. But turning around public perception of the controversial health care reform law in a politically charged mid-term election year poses an enormous challenge for the department's next leader, policy experts said.